SCHEMBL30100249

SCHEMBL30100249

O=C(CCCC(=O)Nc1ccc2nccnc2c1)NO

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 13/20 0.55
HDAC6 Q9UBN7 12/20 0.55
HDAC3 O15379 11/20 0.55
HDAC2 Q92769 11/20 0.55
HDAC11 Q96DB2 10/20 0.55
HDAC8 Q9BY41 10/20 0.55
HDAC10 Q969S8 9/20 0.55
HDAC4 P56524 8/20 0.55
HDAC7 Q8WUI4 8/20 0.55
HDAC9 Q9UKV0 8/20 0.55
HDAC5 Q9UQL6 8/20 0.55
NOTUM Q6P988 1/20 0.51
KDM4E B2RXH2 5/20 0.50
ALDH1A1 P00352 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
MAPT P10636 3/20 0.50
NPC1 O15118 3/20 0.50
HPGD P15428 3/20 0.50
RAB9A P51151 3/20 0.50
NCOR2 Q9Y618 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25775259 1.00 HDAC1 (0.55) HDAC1HDAC6HDAC3HDAC2HDAC11
SCHEMBL30914249 0.88 ALDH1A1 (0.55) NOTUMKDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL29227032 0.88 ALDH1A1 (0.55) NOTUMKDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL30702196 0.85 ALDH1A1 (0.57) NOTUMKDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL1783365 0.83 SMN1; SMN2 (0.57) NOTUMKDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL28218368 0.82 MAPT (0.58) NOTUMKDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL29639131 0.78 RAB9A (0.57) NOTUMKDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL27022341 0.78 RAB9A (0.57) NOTUMKDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL28167267 0.78 MAPT (0.61) NOTUMKDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL30702167 0.78 KDM4E (0.51) NOTUMKDM4EALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254107-A1 RNA-TARGETING LIGANDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2024-08-01 US disclosed
EP-4337653-A1 RNA-TARGETING LIGANDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME The University of North Carolina at Chapel Hill (US) 2024-03-20 EP disclosed
WO-2022256382-A1 RNA-TARGETING LIGANDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2022-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254107-A1 RNA-TARGETING LIGANDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME TARBP1, RNGTT, NSUN3 HDAC1 3990/4885HDAC6 1839/4885HDAC3 1701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.